Article Text

AB0132 Prevalence of Soluble PAD4 and Anti-PAD4 Antibodies in Autoimmune Diseases- Association to Several Acpas but Not to Shared Epitopes in Patients with Rheumatoid Arthritis
  1. N. Umeda1,
  2. I. Matsumoto1,
  3. Y. Kondo1,
  4. H. Tsuboi1,
  5. Y. Kagami2,
  6. A. Ishigami2,
  7. N. Maruyama2,
  8. T. Sumida1
  1. 1Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba-city
  2. 2Molecular Regulation of Aging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan


Background Anti-citrullinated proteins/peptides antibodies (ACPAs) are major predictor of disease severity of patients with rheumatoid arthritis (RA). Citrullination is the post-translational modification mediated by peptidylarginine deiminases (PADs). PAD4, one of the PAD isozyme, is expressed in granulocytes and monocytes, as well as in the synovial lining cells of RA synovium. However, the specificity and prevalence of plasma PAD4 and anti-PAD4 antibodies (Abs) have not yet to be defined. Further, association of PAD4 and anti-PAD4 with ACPAs, HLA-DRB1 shared epitope (SE) alleles and disease activity were not clear.

Objectives To investigate the prevalence of PAD4 and anti-PAD4 Abs in autoimmune diseases and to clarify their association with ACPAs, SE and disease activity in patients with RA.

Methods Levels of human PAD4 and anti-PAD4 Abs in serum or plasma were measured by sandwich ELISA. Samples were obtained from patients with RA (n=48), systemic lupus erythematosus (SLE; n=36), or Sjögren's syndrome (SS; n=37) and from healthy controls (HC; n=40). Antibodies against cyclic citrullinated glucose-6-phosphate isomerase (CCG)-2, -7, anti-citrullinated alpha enolase-1 (CEP-1), and anti-CCP Abs were also measured by ELISA. Patients with RA were genotyped for HLA-DRB1. The levels of human PAD4 and anti-PAD4 Abs were compared with the levels of ACPAs and SE alleles in patients with RA.

Results The mean levels of PAD4 were 111.9 U/ml in patients with RA, 30.4 U/ml in SLE, 81.9 U/ml in SS, and 46.6 U/ml in HC. The PAD4 levels were significantly higher in RA than in SLE or HC (P<0.01). Anti-PAD4 Abs were detected in 44 of the 148 patients with RA (29.7%), but not in patients with SLE or SS and in the HC. In RA patients, the PAD4 levels in the anti-PAD4-negative group were significantly higher than those in the anti-PAD4-positive group. Moreover, the anti-CCG-2, -7, CEP-1, and anti-CCP Ab levels were significantly higher in the anti-PAD4-positive group than in the anti-PAD4-negative group. In RA patients, the PAD4 levels were not correlated with the anti-CCG-2, -7, CEP-1, or CCP Abs, and with the CRP, ESR, RF, MMP-3, IgG, or DAS28-CRP levels. Neither PAD4 nor anti-PAD4 Abs were statistically correlated with the presence of SE alleles.

Conclusions PAD4 levels were higher in RA patients than in SLE patients or HC. Anti-PAD4 Abs appeared specifically in patients with RA and were associated with ACPA levels but not with SE.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.